SEC Form 4 · accession 0001179022-16-000094
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Callicutt
Officer — Chief Financial Officer
Period of report
Jan 20, 2016
Accepted (ET)
Jan 22, 2016 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.37 | Jan 20, 2016 | A | 38,000 | A | — | Jan 20, 2026 | Common Stock | 38,000 | 38,000 | D |
Explanation of responses
- F1The options vest as follows: 25% immediately, and the remaining 75% in equal installments on a monthly basis over a period of three years.